FDA Lifts Clinical Hold on Neurizon Therapeutics’ ALS Drug NUZ-001, Clearing Path for Phase 2/3 Trial

Neurizon Therapeutics Limited has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001, a key step forward in the company’s efforts to develop new treatments for amyotrophic lateral sclerosis (ALS).

The regulatory green light paves the way for NUZ-001 to enter Phase 2/3 clinical testing as part of the prestigious HEALEY ALS Platform Trial. The trial is expected to begin in the fourth quarter of calendar year 2025.

Neurizon’s CEO and Managing Director Dr. Michael Thurn described the FDA’s decision as a major milestone for both the company and the ALS community.

“The FDA’s clearance of our IND application marks a significant milestone in our mission to bring NUZ-001 closer to patients living with ALS,” said Dr. Thurn. “This achievement reflects our unwavering commitment to rigorous scientific and clinical development and the tireless dedication of our team.”

Dr. Thurn also credited the vital support of key opinion leaders and patient advocacy groups, whose involvement helped advance the program toward regulatory approval.

NUZ-001 targets TDP-43 pathology, a hallmark of ALS and other neurodegenerative diseases. Preclinical studies have shown promising data, and the drug has demonstrated encouraging survival outcomes in an Open-Label Extension (OLE) study in ALS patients. Neurizon believes these results support the potential of NUZ-001 to meaningfully slow disease progression.

Opening an Investigational New Drug (IND) application for NUZ-001 also lays a strategic foundation for Neurizon’s broader therapeutic platform. According to the company, the IND will streamline future development efforts by providing a validated regulatory framework for safety, manufacturing, and trial design.

The platform is further bolstered by a licensing agreement with Elanco, which provides robust preclinical safety data and detailed manufacturing and quality documentation. These assets are expected to accelerate NUZ-001’s development and enhance regulatory confidence as the company explores additional indications.

Neurizon is now actively collaborating with the HEALEY ALS Platform Trial team to prepare for trial initiation. With FDA clearance secured, the company is positioned to advance one of its most promising candidates in the fight against ALS, a devastating neurodegenerative disease with limited treatment options.